Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
Trailokya Vijaya Vati is an Ayurvedic solution to the widely prevalent issue
In its endeavor to offer a sustainable, herbal and ayurvedic solution for menstrual cramps, India’s first research to retail venture in the Ayurvedic Cannabis (Bhang) sector, HempStreet recently launched the medicinal cannabis-based Trailokya Vijaya Vati.
Based on the initial feedback study at HempStreet with over 2,000 Ayurveda practitioners across India, Trailokya Vijaya Vati has proven to be extremely effective and the same is true from the massive adoption that it has witnessed in a brief period of time.
Shrey Jain, Co-Founder, HempStreet said, “Menstruation as a topic is highly stigmatized in our country. Period pain is often ignored by making a significant part of women lifestyle and working hours stressful and painful. But the fact is that women have even described the cramping pain as ’almost as bad as having a heart attack.’ On average, a woman goes through around 450 menstrual cycles throughout her lifetime. Irony is that the available solutions in modern medical science possess threat of serious harmful effects in case of long term consumption. Trailokya Vijaya Vati aims at providing a reliable, safe and ayurvedic solution to the women of 21st century.”
“Hempstreet is working in conjunction with top-notch scientists to conduct R&D around safe medication by leveraging the immense potential and natural power of Cannabis. Today HempStreet boasts of 15 approved products and a world-class research partnership with Council of Scientific and Industrial Research (CSIR),” he further added.
HempStreet has recently secured $1,000,000 ( approximately Rs 8 Crore) in Pre-Series A Funding round. This Pre-Series A funding was led by Pharmacon Holdings, a US based Pharma Tech company and Romain Berberis, a long time Private Investor in the Cannabis space in the US and Canada. The company has plans to utilize the funds for category disruption, tech development, research and brand building.